SAN DIEGO, Oct. 22, 2013 /PRNewswire/ -- Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of breast cancer. Polaris Group has previously filed another IND under which it is conducting clinical trials on ADI-PEG 20 for the treatment of multiple other indications, including hepatocellular carcinoma. The latter indication is already in a global Phase 3 study.
"We are pleased to file another IND with the FDA and expand the portfolio of indications for which ADI-PEG 20 is under development. We look forward to initiating a clinical study of ADI-PEG 20 in breast cancer, and also to initiating other studies of ADI-PEG 20," said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Group. "The proposed breast cancer study will combine ADI-PEG 20 with doxorubicin, a first-line therapy in breast cancer. ADI-PEG 20 combination studies are currently underway with docetaxel in prostate cancer and non-small cell lung carcinoma, and with cisplatin in melanoma. We believe its novel mechanism of action and well documented tolerability makes ADI-PEG 20 an ideal candidate to combine with other agents, including cytotoxics."
About ADI-PEG 20
ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of a
|SOURCE Polaris Group|
Copyright©2012 PR Newswire.
All rights reserved